Ganoderic acids from ganoderma lucidum: Inhibitory activity of osteoclastic differentiation and structural criteria

Planta Medica

Volumn 76, Issue 2, 2010, Pages 137-139

  Liu, Jie ^a   Shiono, Jun ^a   Shimizu, Kuniyoshi ^a   Kondo, Ryuichiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Ganoderic acids; Ganoderma lucidum; Ganodermataceae; Osteoclastic differentiation; Triterpenoids

Indexed keywords

ANTIINFLAMMATORY AGENT; CARBONYL DERIVATIVE; GANODERIC ACID D; GANODERIC ACID DM; GANODERIC ACID F; GANODERIC ACID G; GANODERIC ACID I; TRITERPENOID; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CYTOTOXICITY; DRUG STRUCTURE; FUNGUS; GANODERMA LUCIDUM; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS;

ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE; LANOSTEROL; MACROPHAGES; MICE; OSTEOCLASTS; PLANT EXTRACTS; REISHI;

GANODERMA LUCIDUM; GANODERMATACEAE;

EID: 74349111528     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1186035     Document Type: Article

References (12)

1. Manolagas S C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000 21 115-137
2. Suda T, Takahashi N, Martin T J. Modulation of osteoclast differentiation. Endocr Rev 1992 13 66-80
3. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007 40 251-264
4. Tang W, Hemm I, Bertram B. Recent development of antitumor agents from Chinese herbal medicines. Part II. High molecular compounds. Planta Med 2003 3 193-201 (Pubitemid 36470121)
5. Hikino H, Mizuno T. Hypoglycemic actions of some heteroglycans of Ganoderma lucidum fruit bodies. Planta Med 1989 4 385 (Pubitemid 19203290)
6. Miyamoto I, Liu J, Shimizu K, Sato M, Kukita A, Kukita T, Kondo R. Regulation of osteoclastogenesis by ganoderic acid DM isolated from Ganoderma lucidum. Eur J Pharmacol 2009 602 1-7
7. Yue Q X., Xie F B., Guan S H., Ma C, Yang M, Jiang B H., Liu X, Guo D A. Interaction of Ganoderma triterpenes with doxorubicin and proteomic characterization of the possible molecular targets of Ganoderma triterpenes. Cancer Sci 2008 99 1461-1470
8. Komoda Y, Nakamura H, Ishihara S, Uchida M, Kohda H, Yamasaki K. Structures of new terpenoid constitutents of Ganoderma lucidum (FR.) KARST. (Polyporaceas). Chem Pharm Bull 1985 33 4829-4835
9. 13C-NMR assignments of lanostanoids from Ganoderma lucidum by 2D-NMR studies. J Nat Prod 1988 51 54-59
10. Liu J, Kurashiki K, Shimizu K, Kondo R. Structure activity relationship for inhibition of 5: reductase by triterpenoids isolated from Ganoderma lucidum. Bioorg Med Chem 2006 14 8654-8660
11. Watanabe T, Kukita T, Kukita A, Wada N, Toh K, Nagata K, Nomiyama H, Iijima T. Direct stimulation of osteoclastogenesis by MIP-1: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL. J Endocrinol 2004 180 193-201
12. Liu J, Shiono J, Shimizu K, Yu H S., Zhang C Z., Jin F X., Kondo R. 20(R)-Ginsenoside Rh2, not 20(S), is a selective osteoclastogenesis inhibitor without any cytotoxicity. Bioorg Med Chem Lett 2009 19 3320-3323